Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022. The presentation will be accessible on the Alterity website under News on Monday, January ...
Category: Investor Announcement
Initiation of Phase 2 Clinical Trial Expected in CY Q1 2022 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has authorized Alterity’s Phase 2 clinical trial for ATH434 ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that David Stamler, M.D., Chief Executive Officer will participate in two upcoming virtual investor events: MST Financial Lifesciences & Biotech Fourm Wednesday, November 24th at 5:20 p.m. PST (U.S.) / Thursday, ...
AGM 2021 Presentation
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced a poster presentation and accompanying video were delivered at the American Autonomic Society 32nd Annual Internation Symposium on the Autonomic Nervous System. The poster, entitled, Cardiovascular safety and pharmacokinetics of ATH434, ...
Colorectal impairment reversed in a preclinical model of Parkinson’s Disease ATH434 presents a novel mechanism of action for the treatment of neurodegenerative diseases Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced the publication of two preclinical studies demonstrating ...
Highlights: New details on ATH34 Phase 2 clinical trial released. Data from bioMUSE presented at International Parkinson and Movement Disorder Society Congress. Expanded intellectual property portfolio positions future opportunities. Cash balance as of 30 September 2021 of A$41.3M. Quarterly operating cash outflow of $4.9M as expected and in-line with clinical trial activity. Alterity Therapeutics Limited ...
– Clinical trial to enroll patients with early-stage Multiple Systems Atrophy (MSA) – – Expanding bioMUSE Natural History Study – Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced an expansion of the clinical development program for the Company’s lead ...
Study Results Successfully Inform the Design of ATH434 Phase 2 Clinical Trial Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that data was presented from the Company’s Biomarkers of progression in Multiple System Atrophy (bioMUSE) study at the International ...
XBRL 30 June 2021 filed with the SEC